Amendments to the Claims:

The listing of claim will replace all prior versions and listings of claims in the application:

Claims 1-91. (~~Previously~~ canceled).

92. (currently amended) An isolated nucleic acid molecule encoding a fusion protein, comprising

(a) ~~a nucleotide sequence encoding~~ a vascular endothelial growth factor (VEGF) receptor component having immunoglobulin-like (Ig) domains consisting ~~essentially~~ of an ~~immunoglobulin-like (Ig)~~ Ig domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor; and

(b) ~~a nucleotide sequence encoding~~ a multimerizing component.

93. (previously presented) The isolated nucleic acid molecule of claim 92, wherein the first VEGF receptor is Flt1.

94. (previously presented) The isolated nucleic acid molecule of claim 92, wherein the second VEGF receptor is Flk1 or Flt4.

95. (previously presented) The isolated nucleic acid molecule of claim 92, wherein the nucleotide sequence encoding a first VEGF receptor component is upstream of the nucleotide sequence encoding a second VEGF receptor component.

96. (previously presented) The isolated nucleic acid molecule of claim 92, wherein the nucleotide sequence encoding a first VEGF receptor component is downstream of the nucleotide sequence encoding a second VEGF receptor component.

97. (previously presented) The isolated nucleic acid of claim 92, wherein the multimerizing component comprises an immunoglobulin domain.

98. (currently amended) The isolated nucleic acid of claim 97, wherein the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, and the heavy chain of IgG~~, and the light chain of IgG~~.

99. (previously presented) The isolated nucleic acid molecule of claim 92, comprising a nucleic acid sequence selected from:

(a) SEQ ID NOs:3, 5, 7, 9, 11, 13, or 15; and

(b) nucleic acid sequences which, as a result of the degeneracy of the genetic code, differ from the nucleic acid sequence of SEQ ID NOs:3, 5, 7, 9, 11, 13, or 15.

100. (previously presented) The isolated nucleic acid molecule of claim 92, wherein the components of the fusion polypeptide are arranged as 1,2,3; 1,3,2; 2,1,3; 2,3,1; 3,1,2; or 3,2,1, wherein 1 is the first VEGF receptor component, 2 is the second VEGF receptor component, and 3 is the multimerizing component.

101-103. (canceled)

104. (previously presented) An expression vector comprising the nucleic acid molecule of claim 92.

105. (previously presented) A host-vector system for the production of a fusion polypeptide comprising the expression vector of claim ~~105~~ 104, in a suitable host cell.

106. (previously presented) The host-vector system of claim 105, wherein the host cell is a bacterial cell, yeast cell, insect cell, or mammalian cell.

107. (previously presented) The host-vector system of claim 106, wherein the host cell is selected from the group consisting of *E. coli* and CHO.

108. (previously presented) A method of producing a fusion polypeptide, comprising growing cells of the host-vector system of claim 105, under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.

109-131. (canceled)

132. (New) An isolated nucleic acid molecule, consisting of:

a nucleotide sequence encoding immunoglobin-like (Ig) domain 2 of a first VEGF receptor upstream of a nucleotide sequence encoding Ig domain 3 of a second VEGF receptor and a nucleotide sequence encoding a multimerizing component.

133. (New) The isolated nucleic acid molecule of claim 132, wherein the first VEGF receptor is chosen from Flt-1.

134. (New) The isolated nucleic acid molecule of claim 132, wherein the second VEGF receptor is chosen from Flk-1 and Flt-4.

135. (New) The isolated nucleic acid molecule of claim 132, wherein the multimerizing component is chosen from the Fc domain of IgG and the heavy chain of IgG.

136. (New) The isolated nucleic acid molecule of claim 132 which is SEQ ID NO:15.

137. (New) An isolated nucleic acid molecule which is the nucleic acid sequence of SEQ ID NO:15.